Results 141 to 150 of about 55,011 (304)

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Trends in diabetes medication prescribing from 2018 to 2021: A cross-sectional analysis.

PLoS ONE
Several new classes of medications for diabetes have recently become available newer medication classes have been increasing in use. It is unclear how their utilization varied across provinces and how the COVID-19 pandemic may have affected these trends.
Jessica Riad, Fred Abdelmalek, Noah Ivers, Mina Tadrous   +3 more
doaj   +1 more source

Decision letter for "Cardiovascular risk profiles: A cross‐sectional study evaluating the generalisability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials Rewind , Leader and Sustain ‐6 to the real‐world type 2 diabetes population in the UK"

, 2021

openalex   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Vision impairment following glucagon-like peptide-1 receptor agonist use: is it harmful? [PDF]

Maria Cecilia Bahit, Michael K. Gibson, Martyna Kuleta, Łukasz Szarpak, Krzysztof Piotr Malinowski, Iwona Kowalska‐Bobko, Zbigniew Siudak   +6 more
openalex   +1 more source

Development of NAFLD‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation

Cell Proliferation, EarlyView.
Microporous array organ chips were integrated with commercially available well plates to develop organoid chip platforms, which enable modelling of hepatic physiology and non‐alcoholic fatty liver disease (NAFLD) pathogenesis, as well as evaluation of semaglutide therapeutics. ABSTRACT Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate
Xiao‐yan You, Xiang‐yang Li, Hui Wang, Guo‐ping Zhao   +3 more
wiley   +1 more source

A Meta-Analysis of the Effects of Glucagon-Like-Peptide 1 Receptor Agonist (GLP1-RA) in Nonalcoholic Fatty Liver Disease (NAFLD) With Type 2 Diabetes (T2D) [PDF]

, 2021
Samit Ghosal, Debasis Datta, Binayak Sinha   +2 more
openalex   +1 more source

The Voice of a Disease: Why Food Noise Can No Longer Be Ignored!

Obesity, EarlyView.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing. Materials and Methods This 12‐week Phase 1, randomised, placebo‐controlled, participant‐ and investigator‐blinded, multiple ascending dose study evaluated the ...
Shobha Bhattachar, Lai San Tham, Beth Tidemann‐Miller, Hilda Ibriga, Hongchang Qu, Daniel A. Briere, Axel Haupt, Kieren J. Mather, Edward Pratt   +8 more
wiley   +1 more source

Review for "Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis"

, 2019

openalex   +1 more source